FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311524582> ?p ?o ?g. }

• W4311524582 endingPage "116" @default.
• W4311524582 startingPage "114" @default.
• W4311524582 abstract "European Journal of Heart FailureVolume 25, Issue 1 p. 114-116 Invited Editorial Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone Andreas P. Kalogeropoulos, Corresponding Author Andreas P. Kalogeropoulos [email protected] Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA Corresponding author. Stony Brook University Medical Center, 101 Nicolls Road, Health Sciences Center, T-16-080, Stony Brook, NY 11794-8167, USA. Tel: +1 631 638-0081, Fax: +1 631 444-1054, Email: [email protected]Search for more papers by this authorMark Jacobs, Mark Jacobs Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USASearch for more papers by this author Andreas P. Kalogeropoulos, Corresponding Author Andreas P. Kalogeropoulos [email protected] Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA Corresponding author. Stony Brook University Medical Center, 101 Nicolls Road, Health Sciences Center, T-16-080, Stony Brook, NY 11794-8167, USA. Tel: +1 631 638-0081, Fax: +1 631 444-1054, Email: [email protected]Search for more papers by this authorMark Jacobs, Mark Jacobs Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USASearch for more papers by this author First published: 15 December 2022 https://doi.org/10.1002/ejhf.2757 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2726 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al.; Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002; 40: 970–5. 2Waagstein F, Stromblad O, Andersson B, Bohm M, Darius M, Delius W, et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2003; 5: 679–91. 3Li T, Yuan G, Ma C, Jin P, Zhou C, Li W. Clinical efficacy of carvedilol treatment for dilated cardiomyopathy: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019; 98:e15403. 4Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002; 40: 304–10. 5Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc. 2019; 8:e012272. 6Shi FH, Li H, Shen L, Xu L, Ge H, Gu ZC, et al. Beneficial effect of sodium-glucose co-transporter 2 inhibitors on left ventricular function. J Clin Endocrinol Metab. 2022; 107: 1191–203. 7Adabag S, Roukoz H, Anand IS, Moss AJ. Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis. J Am Coll Cardiol. 2011; 58: 935–41. 8Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF, et al.; TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circ Heart Fail. 2014; 7: 104–15. 9Jolobe OM. Evolving strategies for the use of spironolactone in cardiovascular disease. Eur J Intern Med. 2013; 24: 303–9. 10Nicoletti A, Heudes D, Hinglais N, Appay MD, Philippe M, Sassy-Prigent C, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension. 1995; 26: 101–11. 11Baldo MP, Forechi L, Morra EA, Zaniqueli D, Machado RC, Lunz W, et al. Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness. Pharmacol Rep. 2011; 63: 975–82. 12Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005; 26: 2193–9. 13Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res. 2002; 25: 837–42. 14Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al.; Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013; 309: 781–91. 15Kosmala W, Przewlocka-Kosmala M, Marwick TH. Association of active and passive components of LV diastolic filling with exercise intolerance in heart failure with preserved ejection fraction: mechanistic insights from spironolactone response. JACC Cardiovasc Imaging. 2019; 12: 784–94. 16Shah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS, et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail. 2015; 8: 1052–8. 17 Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, et al. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. Eur J Heart Fail. 2023; 25: 108–13. 18Nauta JF, Hummel YM, van der Meer P, Lam CSP, Voors AA, van Melle JP. Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2018; 20: 1303–11. 19Zhou H, Peng W, Li F, Wang Y, Wang B, Ding Y, et al. Effect of sodium-glucose cotransporter 2 inhibitors for heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med. 2022; 9:875327. 20Costanzo P, Savarese G, Rosano G, Musella F, Casaretti L, Vassallo E, et al. Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients. Int J Cardiol. 2013; 167: 2757–64. 21Jin X, Nauta JF, Hung CL, Ouwerkerk W, Teng TK, Voors AA, et al. Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis. Heart Fail Rev. 2022; 27: 1933–55. 22Ravassa S, Lopez B, Ferreira JP, Girerd N, Bozec E, Pellicori P, et al.; HOMAGE Trial Committees and Investigators. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. Eur J Heart Fail. 2022; 24: 321–31. 23Segar MW, Patel KV, Ayers C, Basit M, Tang WHW, Willett D, et al. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. Eur J Heart Fail. 2020; 22: 148–58. Volume25, Issue1January 2023Pages 114-116 ReferencesRelatedInformation" @default.
• W4311524582 created "2022-12-26" @default.
• W4311524582 creator A5007180055 @default.
• W4311524582 creator A5020036899 @default.
• W4311524582 date "2023-01-01" @default.
• W4311524582 modified "2023-10-16" @default.
• W4311524582 title "Improve heart function to improve heart failure outcomes: the d <scp>isease‐modifying</scp> effects of spironolactone" @default.
• W4311524582 cites W1548375036 @default.
• W4311524582 cites W1883738259 @default.
• W4311524582 cites W1981192561 @default.
• W4311524582 cites W1991059205 @default.
• W4311524582 cites W2021603656 @default.
• W4311524582 cites W2083662856 @default.
• W4311524582 cites W2094350418 @default.
• W4311524582 cites W2097198666 @default.
• W4311524582 cites W2109177794 @default.
• W4311524582 cites W2113829060 @default.
• W4311524582 cites W2137403077 @default.
• W4311524582 cites W2154395080 @default.
• W4311524582 cites W2772316063 @default.
• W4311524582 cites W2807672736 @default.
• W4311524582 cites W2954586029 @default.
• W4311524582 cites W2972570940 @default.
• W4311524582 cites W2982039390 @default.
• W4311524582 cites W3212191081 @default.
• W4311524582 cites W3215278046 @default.
• W4311524582 cites W4210820127 @default.
• W4311524582 cites W42816708 @default.
• W4311524582 cites W4285741720 @default.
• W4311524582 cites W4307495033 @default.
• W4311524582 doi "https://doi.org/10.1002/ejhf.2757" @default.
• W4311524582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36519691" @default.
• W4311524582 hasPublicationYear "2023" @default.
• W4311524582 type Work @default.
• W4311524582 citedByCount "0" @default.
• W4311524582 crossrefType "journal-article" @default.
• W4311524582 hasAuthorship W4311524582A5007180055 @default.
• W4311524582 hasAuthorship W4311524582A5020036899 @default.
• W4311524582 hasConcept C126322002 @default.
• W4311524582 hasConcept C164705383 @default.
• W4311524582 hasConcept C2776379505 @default.
• W4311524582 hasConcept C2778198053 @default.
• W4311524582 hasConcept C71924100 @default.
• W4311524582 hasConceptScore W4311524582C126322002 @default.
• W4311524582 hasConceptScore W4311524582C164705383 @default.
• W4311524582 hasConceptScore W4311524582C2776379505 @default.
• W4311524582 hasConceptScore W4311524582C2778198053 @default.
• W4311524582 hasConceptScore W4311524582C71924100 @default.
• W4311524582 hasIssue "1" @default.
• W4311524582 hasLocation W43115245821 @default.
• W4311524582 hasLocation W43115245822 @default.
• W4311524582 hasOpenAccess W4311524582 @default.
• W4311524582 hasPrimaryLocation W43115245821 @default.
• W4311524582 hasRelatedWork W1600434987 @default.
• W4311524582 hasRelatedWork W2076843464 @default.
• W4311524582 hasRelatedWork W2140543320 @default.
• W4311524582 hasRelatedWork W2385975691 @default.
• W4311524582 hasRelatedWork W2387648272 @default.
• W4311524582 hasRelatedWork W2407582814 @default.
• W4311524582 hasRelatedWork W2418241599 @default.
• W4311524582 hasRelatedWork W4247718175 @default.
• W4311524582 hasRelatedWork W4251987652 @default.
• W4311524582 hasRelatedWork W1936130942 @default.
• W4311524582 hasVolume "25" @default.
• W4311524582 isParatext "false" @default.
• W4311524582 isRetracted "false" @default.
• W4311524582 workType "article" @default.